DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dropless vs. Standard Drops Contralateral Eye Study

Information source: Carolina Eyecare Physicians, LLC
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cataract

Intervention: TriMoxiVanc (Drug); Moxifloxacin HCl 0.5% (Drug); Ilevro (Drug); Prednisolone acetate 1% (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Carolina Eyecare Physicians, LLC

Official(s) and/or principal investigator(s):
Kerry D Solomon, MD, Principal Investigator, Affiliation: Carolina Eyecare Physicians, LLC

Overall contact:
Helga P Sandoval, MD, MSCR, Phone: 8434780915, Email: helga.sandoval@carolinaeyecare.com

Summary

To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.

Clinical Details

Official title: Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Change from baseline (preoperative exam) in macular thickness

Detailed description: Key factors for a successful cataract surgery include, among others, preoperative measurements for accurate intraocular lens (IOL) calculation, surgical technique and surgeon's experience but also the use of prophylactic topical antibiotics and anti-inflammatories (steroidal and non-steroidal, NSAID) to decrease the risk of postoperative infection (i. e. endophthalmitis) and intraocular inflammation (i. e. macular edema, CME). Even though, the large body of literature that supports the significance of prophylactic eye drops prior to surgery, patient compliance is a common problem. Different factors have been associated with patient's lack of compliance. It could be due to patient's inability to self administer the drops, lack of understanding of the importance of using the prophylactic treatment as well as understanding the instructions of how to administer the drops and its storage, or just forgetfulness or the fact that they don't like to put the drops multiple times a day for 2-4 weeks, therefore they just avoid doing it. There is a new option called "Dropless cataract surgery". This modality of treatment involves the injection of an eye compatible compound at time of cataract surgery. The purpose of is to assess the efficacy the compound injected during routine cataract surgery and intraocular (IOL) implantation with and without a topical NSAID compared to standard prophylactic treatment that includes the topical use of Moxifloxacin, Ilevro, and Prednisolone acetate 1%.

Eligibility

Minimum age: 50 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subject is undergoing bilateral cataract extraction or refractive lens exchange with

intraocular lens implantation.

- Willing and able to provide written informed consent for participation in the study.

- Willing and able to comply with scheduled visits and other study procedures.

- Willing and able to administer eye drops and record the times the drops were

instilled.

- Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes

within 6-15 days between surgeries.

- Potential postoperative best-corrected visual acuity of 20/30 or better

Exclusion Criteria:

- Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative

diabetic retinopathy, shallow anterior chamber, macular edema, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.

- Presence of epiretinal membrane.

- Uncontrolled diabetes.

- Use of any systemic or topical drug known to interfere with visual performance.

- Contact lens use during the active treatment portion of the trial.

- Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis.

- History of chronic intraocular inflammation.

- History of retinal detachment.

- Pseudoexfoliation syndrome or any other condition that has the potential to weaken

the zonules.

- Previous radial keratotomy.

- Any additional ocular surgical procedures at time of cataract extraction (i. e.

iStent) except corneal incisions for the correction of astigmatism.

- Anesthesia other than topical anesthesia (i. e. retrobulbar, general, etc).

- Any clinically significant, serious or severe medical or psychiatric condition that

may increase the risk associated with study participation or may interfere with the interpretation of study results.

- Participation in (or current participation) any investigational drug or device trial

within the previous 30 days prior to the start date of this trial.

- Intraocular conventional surgery within the past three months or intraocular laser

surgery within one month.

Locations and Contacts

Helga P Sandoval, MD, MSCR, Phone: 8434780915, Email: helga.sandoval@carolinaeyecare.com

Minnesota Eye Consultants, P.A., Bloomington, Minnesota 55431, United States; Recruiting
Madeline Garner, Phone: 952-567-6128, Email: mcgarner@mneye.com

Associated Eye Care, Stillwater, Minnesota 55082, United States; Recruiting
Terri Flom, Phone: 651-275-3000, Email: tflom@AssociatedEyeCare.com

Ophthalmic Consultants of Long Island, Garden City, New York 11530, United States; Recruiting
Kimbel Martin, Email: kmartin@ocli.net

Carolina Eyecare Physicians, LLC, Mt. Pleasant, South Carolina 29464, United States; Recruiting
Helga P Sandoval, MD, MSCR, Phone: 843-881-3937, Email: helga.sandoval@carolinaeyecare.com
Kerry D Solomon, MD, Principal Investigator
Jefrrey F Hood, OD, Sub-Investigator

Additional Information

Starting date: January 2015
Last updated: July 31, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017